Genedrive – the near patient molecular diagnostics company – has revealed that the National Institute for Health and Care Excellence (NICE) has started an evaluation of the MT-RNR1 test via its Diagnostics Assessment Programme (DAP).
Genedrive’s assay is the world’s first rapid point-of-care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive MT-RNR1 test…
